• Users Online: 90
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 12  |  Issue : 1  |  Page : 92-94

Atypical stress femoral shaft fracture secondary to alendronate therapy

1 Medical Research, Francisco Marroquín University, Guatemala
2 Department of Traumatology and Orthopaedics, Centro Médico Hospital, Guatemala

Correspondence Address:
Dr. Mario Cahueque
6a Ave., 7-39 Zona 10 Edificio las Brisas 4to Nivel, Guatemala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jotr.jotr_11_20

Rights and Permissions

Bisphosphonate (BP) therapy is widely used as it remains the first-line of treatment for osteoporosis. These antiresorptive drugs inhibit osteoclast function and promote apoptosis. However, atypical stress femoral fractures occurring in the diaphysis and subtrochanteric region are linked to prolonged BP use. The risk of fracture is directly proportional to the time exposed to the treatment. Ongoing BP exposure prevents bone resorption and replacement in areas with accumulated microdamage through targeted remodeling. Therefore, long-term BP use (more than 5 years) is an important risk factor. Atypical femoral fractures remain very rare, and the benefits of BP therapy for osteoporotic fracture prevention and treatment outweigh the risk. The present report consists of a rare case of a patient with an atypical diaphyseal femoral stress fracture secondary to prolonged alendronate use.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal